Is Antiplatelet Treatment Effective on the Progression of White Matter Hyperintensity? - 5 Year Follow Up, Propensity Score Adjusted, Observational Study (P04.203)

Rha, Joung‐Ho; Park, Hee-Kwon; Park, Jeong Jin; Yoo, Na-Young

doi:10.1212/wnl.78.1_meetingabstracts.p04.203

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although antiplatelet agents have been extensively evaluated in the primary and secondary prevention of patients with lacunar stroke, there have been few studies examining the cerebrovascular effects of antiplatelet agents in healthy populations. In one small study, healthy subjects who underwent MRI screening for WMH were given antiplatelet therapy [203,204]. In a follow-up MRI study 5 years later, there was no difference in deep or periventricular WMH progression among patients taking antiplatelet agents.…”

Section: Treatment and Future Directionsmentioning

confidence: 99%

Asymptomatic Cerebral Small Vessel Disease: Insights from Population-Based Studies

et al. 2019

View full text Add to dashboard Cite

Cerebral small vessel disease (CSVD) is a common group of neurological conditions that confer a significant burden of morbidity and mortality worldwide. In most cases, CSVD is only recognized in its advanced stages once its symptomatic sequelae develop. However, its significance in asymptomatic healthy populations remains poorly defined. In population-based studies of presumed healthy elderly individuals, CSVD neuroimaging markers including white matter hyperintensities, lacunes, cerebral microbleeds, enlarged perivascular spaces, cortical superficial siderosis, and cerebral microinfarcts are frequently detected. While the presence of these imaging markers may reflect unique mechanisms at play, there are likely shared pathways underlying CSVD. Herein, we aim to assess the etiology and significance of these individual biomarkers by focusing in asymptomatic populations at an epidemiological level. By primarily examining population-based studies, we explore the risk factors that are involved in the formation and progression of these biomarkers. Through a critical semi-systematic review, we aim to characterize "asymptomatic" CSVD, review screening modalities, and draw associations from observational studies in clinical populations. Lastly, we highlight areas of research (including therapeutic approaches) in which further investigation is needed to better understand asymptomatic CSVD.

show abstract

Section: Treatment and Future Directionsmentioning

confidence: 99%